BOSULIF 1L Regulatory Submissions Acceptance

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for BOSULIF® (bosutinib) for the Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia.

Applications seek to expand approved use of BOSULIF into first- line treatment based on positive results from Phase 3 head-to-head trial.

Please read full press release here.

 

TwitterLinkedInEmailPrint